Back to Research Hub
Relay Therapeutics, Inc.
RLAY
$14.09+0.43 (+3.15%)
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
StreetsValue research for Relay Therapeutics, Inc. (RLAY)
Members get the full report for Relay Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.